HC Wainwright Forecasts Weaker Earnings for Krystal Biotech

Krystal Biotech, Inc. (NASDAQ:KRYS) – Stock analysts at HC Wainwright dropped their FY2024 earnings per share (EPS) estimates for Krystal Biotech in a research report issued on Monday, November 4th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of $3.64 per share for the year, down from their previous estimate of $4.01. HC Wainwright currently has a “Buy” rating and a $221.00 target price on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $2.88 per share. HC Wainwright also issued estimates for Krystal Biotech’s Q4 2024 earnings at $1.81 EPS, FY2025 earnings at $5.57 EPS, FY2027 earnings at $9.34 EPS and FY2028 earnings at $9.76 EPS.

Several other equities analysts have also commented on the company. Stifel Nicolaus increased their price objective on Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. Chardan Capital lifted their target price on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a research report on Monday, August 5th. Finally, Citigroup boosted their price target on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research note on Tuesday. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $197.00.

Krystal Biotech Stock Up 1.3 %

NASDAQ KRYS opened at $185.45 on Thursday. The stock’s 50-day simple moving average is $181.20 and its two-hundred day simple moving average is $180.29. Krystal Biotech has a twelve month low of $93.95 and a twelve month high of $219.34. The company has a market capitalization of $5.33 billion, a price-to-earnings ratio of 104.77 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The firm had revenue of $83.84 million for the quarter, compared to analysts’ expectations of $82.94 million. During the same quarter last year, the company posted ($0.67) EPS. The business’s quarterly revenue was up 879.9% on a year-over-year basis.

Hedge Funds Weigh In On Krystal Biotech

Several hedge funds and other institutional investors have recently modified their holdings of KRYS. Quest Partners LLC boosted its position in Krystal Biotech by 264.1% during the 3rd quarter. Quest Partners LLC now owns 1,398 shares of the company’s stock valued at $254,000 after acquiring an additional 1,014 shares in the last quarter. Swiss National Bank lifted its stake in shares of Krystal Biotech by 8.0% in the 3rd quarter. Swiss National Bank now owns 39,100 shares of the company’s stock valued at $7,117,000 after purchasing an additional 2,900 shares during the period. Huntington National Bank boosted its position in shares of Krystal Biotech by 97.6% during the third quarter. Huntington National Bank now owns 573 shares of the company’s stock valued at $104,000 after purchasing an additional 283 shares in the last quarter. KBC Group NV grew its stake in Krystal Biotech by 25.9% in the third quarter. KBC Group NV now owns 642 shares of the company’s stock worth $117,000 after purchasing an additional 132 shares during the period. Finally, Pier 88 Investment Partners LLC raised its holdings in Krystal Biotech by 5.1% in the third quarter. Pier 88 Investment Partners LLC now owns 3,530 shares of the company’s stock worth $643,000 after purchasing an additional 170 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total value of $4,944,000.00. Following the sale, the insider now directly owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 14.10% of the stock is currently owned by corporate insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).